Navigation Links
GlaxoSmithKline To Post Quarterly US Grants Report
Date:8/21/2008

PHILADELPHIA, Aug. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that, beginning in February 2009, the company will proactively report educational and charitable grants provided to US health-related organizations. The report will be updated on a quarterly basis and will include grants provided to various organizations including hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups, and continuing medical education companies.

GSK provides grants for programs and organizations that foster increased understanding of scientific, clinical, and healthcare issues, and contribute to the enhancement of patient care.

"GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge about health-related issues," said Chris Viehbacher, President, North American Pharmaceuticals, GlaxoSmithKline. "By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients."

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at http://us.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
4. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
5. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
6. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
7. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
8. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
9. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
10. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
11. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... VTI, Vertebral Technologies, Inc., announces the successful outcome of the first lumbar ... 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... capable of performing routine electrochemical biosensing has increased dramatically. Primarily driven by ... detection and quantification of various analytes in complex samples. , ...
(Date:1/12/2017)... , ... January 12, 2017 , ... ... targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to ... new drug combination that has stabilized Rosendahl’s disease and increased both the quantity ...
(Date:1/12/2017)...   Protein Sciences Corporation , a leading ... Influenza Vaccine ®, announced today that its lead ... results and induced strong neutralizing antibodies against the ... expected to advance into human clinical trials in ... of Technology in Immunobiologicals of the Oswaldo Cruz ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/12/2016)... 2016  Researchers at Trinity College, Dublin, are ... combining the material with Silly Putty. The mixture (known ... able to sense pulse, blood pressure, respiration, and ... The research team,s findings were published ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):